Altay Therapeutics, Inc. — SEC Form D Filing

Altay Therapeutics, Inc. filed an SEC Form D on October 2, 2026, reporting $15.74M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
October 2, 2026
Amount reported
$15.74M
Round stage
Seed
Industry
Biotechnology
Website
https://www.altaytherapeutics.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Many serious diseases, including facioscapulohumeral muscular dystrophy (FSHD), chronic inflammatory diseases, and various cancers, represent unmet medical needs for patients with limited treatment options. These conditions are often driven by transcription factors like DUX4 and STAT3, which have historically been considered 'undruggable'.

Solution

Altay Therapeutics is developing oral small molecule inhibitors that target transcription factors such as DUX4 for FSHD, and STAT3 for inflammatory diseases and oncology. These inhibitors are designed to bind to novel allosteric sites on transcription factors, enabling the development of therapies for previously 'undruggable' targets.

Why now

Advances in understanding protein dynamics and allosteric sites, coupled with high-throughput screening technologies, now allow for the design of small molecules that can effectively modulate previously inaccessible transcription factors, opening new therapeutic avenues.

Verdict

Investors backed this seed round for the promise of a novel modality cracking historically difficult targets, not for near-term clinical validation or market entry. The implicit bet was on the scientific premise of allosteric transcription factor inhibition proving out in preclinical models, which would then unlock significantly larger, derisked later-stage capital. This cleared because of the scientific novelty applied to 'undruggable' targets, not because of a clear commercialization path or patient adoption story. The upside was limited by the long development timelines and substantial capital required to translate a scientific breakthrough into an approved therapeutic, even if the initial science held.

Source: SEC EDGAR Form D filing